The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Critical reviews in oncology/hematology

• Publication date

  2008-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.critrevonc.2008.03.002PMID 18424067
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Activity of the histone deacetylase inhibitors LBH589 and LAQ824 in hematologic malignancies

  2009cited by this paper
• Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (panobinostat).

  2008cited by this paper
• Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704

  2007cited by this paper
• A phase II study of vorinostat (NSC 701852 ) in patients (pts) with relapsed non-small cell lung cancer (NSCLC)

  2007cited by this paper
• PD3-1-2: Phase I trial of vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with solid tumors

  2007cited by this paper
• The effect of P53 gene status on the interaction of vorinostat (Suberoylanilide Hydroxamic Acid-SAHA) with carboplatin in non-small cell lung cancer (NSCLC) cell lines

  2007cited by this paper
• Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

  2007cited by this paper
• Histone deacetylase inhibitor NVP-LAQ824 sensitizes human nonsmall cell lung cancer to the cytotoxic effects of ionizing radiation

  2007cited by this paper
• Cancer Statistics, 2007

  2007cited by this paper
• Global histone modifications predict prognosis of resected non small-cell lung cancer.

  2007cited by this paper
• Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor–dependent human lung cancer cells

  2007cited by this paper
• Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid Malignancies

  2007cited by this paper
• Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

  2006cited by this paper
• SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells.

  2006cited by this paper
• Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer.

  2006cited by this paper
• Histone Deacetylase Inhibitors for Cancer Therapy

  2006cited by this paper
• Histone deacetylase inhibitors and cancer: from cell biology to the clinic.

  2005cited by this paper
• Erlotinib in previously treated non-small-cell lung cancer.

  2005cited by this paper
• Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review

  2005influential reference
• Butyric acid and pivaloyloxymethyl butyrate, AN-9, a novel butyric acid derivative, induce apoptosis in HL-60 cells

  2005cited by this paper
• In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines.

  2005cited by this paper
• Drug Insight: histone deacetylase inhibitors—development of the new targeted anticancer agent suberoylanilide hydroxamic acid

  2005cited by this paper
• Clinical development of histone deacetylase inhibitors as anticancer agents.

  2005cited by this paper
• Histone deacetylase inhibitors: insights into mechanisms of lethality

  2005cited by this paper
• Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).

  2005cited by this paper
• Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

  2005cited by this paper
• Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.

  2005cited by this paper
• Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer.

  2004cited by this paper
• American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

  2004cited by this paper
• Preclinical antitumor activity of CI-994

  2004cited by this paper
• Preclinical toxicity of a new oral anticancer drug, CI-994 (Acetyldinaline), in rats and dogs

  2004cited by this paper
• Chronic Oral Administration of CI-994: A Phase I Study

  2004cited by this paper
• Sequence‐specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid

  2004cited by this paper
• Histone deacetylase inhibitors in myelodysplastic syndrome.

  2004cited by this paper
• Dose escalation study of pivanex (a histone deacetylase inhibitor) in combination with docetaxel for advanced non-small cell lung cancer.

  2004cited by this paper
• Histone deacetylases.

  2003cited by this paper
• Molecular sequelae of histone deacetylase inhibition in human malignant B cells.

  2003cited by this paper
• Cell biology (Communication arising): Tubulin acetylation and cell motility

  2003cited by this paper
• Tumor cell‐specific cytotoxicity by targeting cell cycle checkpoints

  2003cited by this paper
• Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?

  2003cited by this paper
• HDAC‐6 interacts with and deacetylates tubulin and microtubules in vivo

  2003cited by this paper
• Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA.

  2003cited by this paper
• Histone Deacetylase Inhibitors in Cancer Therapy

  2003cited by this paper
• Histone Deacetylases: Unique Players in Shaping the Epigenetic Histone Code

  2003cited by this paper
• Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling

  2002cited by this paper
• Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment.

  2002cited by this paper
• Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity.

  2002cited by this paper
• HDAC6 is a microtubule-associated deacetylase

  2002cited by this paper
• Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors.

  2002cited by this paper
• The fundamental role of epigenetic events in cancer

  2002cited by this paper
• Isolation and Characterization of Mammalian HDAC10, a Novel Histone Deacetylase*

  2002cited by this paper
• Increased expression of unmethylated CDKN2D by 5-aza-2′-deoxycytidine in human lung cancer cells

  2001cited by this paper
• Histone deacetylases and transcriptional therapy with their inhibitors

  2001cited by this paper
• Histone acetylation and disease

  2001cited by this paper
• Mechanism for Nucleocytoplasmic Shuttling of Histone Deacetylase 7*

  2001cited by this paper
• Estimating the world cancer burden: Globocan 2000

  2001cited by this paper
• Histone deacetylases and cancer: causes and therapies

  2001cited by this paper
• Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.

  2000cited by this paper
• The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases.

  2000cited by this paper
• Uptake of pivaloyloxymethyl butyrate into leukemic cells and its intracellular esterase-catalyzed hydrolysis

  2000cited by this paper
• Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells.

  2000cited by this paper
• Histone Acetylation Modifiers in the Pathogenesis of Malignant Disease

  2000cited by this paper
• A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.

  1998cited by this paper
• Transcriptional Regulation of the MDR1 Gene by Histone Acetyltransferase and Deacetylase Is Mediated by NF-Y

  1998cited by this paper
• Regulation of activity of the transcription factor GATA-1 by acetylation

  1998cited by this paper
• Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain.

  1997cited by this paper
• Second generation hybrid polar compounds are potent inducers of transformed cell differentiation.

  1996cited by this paper
• Activity of the histone deacetylase inhibitors LBH 589 and LAQ 824 in hematologic malignancies

  year unknowncited by this paper

• CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease.

  2026cites this paper
• Histone modification inhibitors: An emerging frontier in thyroid Cancer therapy.

  2025cites this paper
• The role of histone post-translational modifications in cancer and cancer immunity: functions, mechanisms and therapeutic implications

  2024cites this paper
• Synthetic Approaches, Properties, and Applications of Acylals in Preparative and Medicinal Chemistry

  2024cites this paper
• PM2.5: Epigenetic Alteration in Lung Physiology and Lung Cancer Pathogenesis.

  2023cites this paper
• The role of protein acetylation in carcinogenesis and targeted drug discovery

  2022cites this paper
• Epigenetic Alterations and Inflammation as Emerging Use for the Advancement of Treatment in Non-Small Cell Lung Cancer

  2022cites this paper
• Effects of sodium butyrate-containing calcium sulfate bone graft on oral mucosa and bone tissue

  2022cites this paper
• Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo.

  2020cites this paper
• Antitumor effects of histone deacetylase inhibitor suberoylanilide hydroxamic acid in epidermal growth factor receptor-mutant non-small-cell lung cancer lines in vitro and in vivo

  2018cites this paper
• Rational design and characterization of a DNA/HDAC dual-targeting inhibitor containing nitrogen mustard and 2-aminobenzamide moieties.

  2018cites this paper
• Down-regulation of FOXR2 inhibits non-small cell lung cancer cell proliferation and invasion through the Wnt/β-catenin signaling pathway.

  2018cites this paper
• Explorer Current concepts on the role of inflammation in COPD and lung cancer

  2017influential citation
• TSA increases C/EBP‑α expression by increasing its lysine acetylation in hepatic stellate cells.

  2017cites this paper
• Particulate matter‐induced epigenetic changes and lung cancer

  2017cites this paper
• Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/β-catenin signaling

  2016cites this paper
• The quest for an effective and safe personalized cell therapy using epigenetic tools

  2016cites this paper
• Epigenetic therapy approaches in non-small cell lung cancer: Update and perspectives

  2016cites this paper
• Epigenetic Modifications: Therapeutic Potential in Cancer

  2015cites this paper
• Epigenetic drugs against cancer: an evolving landscape

  2014cites this paper
• Epigenetics in diagnosis, prognostic assessment and treatment of cancer: an update

  2014cites this paper
• Histone deacetylases in cardiac fibrosis: current perspectives for therapy.

  2014cites this paper
• ER homeostasis and motility of NSCLC cell lines can be therapeutically targeted with combined Hsp90 and HDAC inhibitors.

  2013cites this paper
• Role of epigenetics in inflammation-associated diseases.

  2013cites this paper
• Class I HDAC imaging using [3H]CI-994 autoradiography

  2013cites this paper
• Cancer Epigenetics: New Therapies and New Challenges

  2013cites this paper
• Histones and lung cancer: are the histone deacetylases a promising therapeutic target?

  2013cites this paper
• Profile of panobinostat and its potential for treatment in solid tumors: an update

  2013cites this paper
• Preclinical activity of LBH 589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia

  2012cites this paper
• Modulation of Epigenetic Targets for Anticancer Therapy: Clinicopathological Relevance, Structural Data and Drug Discovery Perspectives

  2012cites this paper
• Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia

  2012cites this paper
• Targeted therapies for advanced non-small-cell lung cancer: current status and future implications.

  2012cites this paper
• Epigenetic Mechanisms in Commonly Occurring Cancers

  2012influential citation
• Epigenetic Control of Tumor Suppressor Genes in Lung Cancer

  2012cites this paper
• [COPD and lung cancer: epidemiological and biological links].

  2012cites this paper
• Patho-Epigenetics of Disease

  2012cites this paper
• Epigenetic Reprogramming in Lung Carcinomas

  2012cites this paper
• Tumor suppressor genes

  2012cites this paper
• The Mechanism of Action of the Histone Deacetylase Inhibitor Vorinostat Involves Interaction with the Insulin-Like Growth Factor Signaling Pathway

  2011cites this paper
• The Epithelial Cell and Lung Cancer: The Link between Chronic Obstructive Pulmonary Disease and Lung Cancer

  2011cites this paper
• New molecular targeted therapies for advanced non-small-cell lung cancer.

  2011cites this paper
• Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells

  2011cites this paper
• Environment and the Role of Inflammation in Chronic Pulmonary Diseases: The Silent Mediator

  2011cites this paper
• Preclinical Activity of LBH589 Alone or in Combination with Chemotherapy in a Xenogeneic Mouse Model of Human Acute Lymphoblastic Leukemia

  2011cites this paper
• TRAIL receptor targeting therapies for non-small cell lung cancer: current status and perspectives.

  2010cites this paper
• 3D QSAR of aminophenyl benzamide derivatives as histone deacetylase inhibitors.

  2010cites this paper
• Targeted therapies for non-small cell lung cancer.

  2010cites this paper
• Lung cancer

  2010cites this paper
• Akt Signals through the Mammalian Target of Rapamycin Pathway to Regulate CNS Myelination

  2009cites this paper
• Chronic obstructive pulmonary disease and lung cancer: inflammation, the missing link

  2009cites this paper
• Vorinostat (NSC# 701852) in Patients with Relapsed Non-small Cell Lung Cancer: A Wisconsin Oncology Network Phase II Study

  2009cites this paper
• HDAC inhibitors and ionizing radiation: Combinatorial strategy to combat lung cancer

  2009cites this paper
• Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier

  2009cites this paper
• Current concepts on the role of inflammation in COPD and lung cancer.

  2009influential citation